arrow
M

Michael A. Thompson

University of Ostrava
H指数:63
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data Analysis

PI-Rd三联疗法在复发/难治性多发性骨髓瘤中的疗效与安全性比较:INSIGHT-MM数据分析

2026-01-010
OAAI
Exploratory evaluation of the somatic and immunologic landscape of primary and metastatic cervical cancer to better inform future clinical trial development

原发性与转移性宫颈癌的体细胞及免疫景观的探索性评估,以更好地指导未来临床试验的开发

2025-09-290
PRE
Exploring Gender Differences in Receipt of the 5As for Smoking Cessation for Recently Diagnosed Cancer Patients (ECOG-ACRIN EAQ171CD)
2024-12-190
PRE
A Comprehensive Whole Genome Sequencing Assay Provides Robust Characterization of Clinically Relevant Genomic Alterations across Myeloid Malignancies Concordant with Matched Results from Targeted DNA, Whole Transcriptome RNA and Cytogenetic Profiling

一项全面的基因组测序分析为临床相关的髓系恶性肿瘤基因组改变提供了稳健的表征,其结果与靶向DNA、全转录组RNA和细胞遗传学分析匹配的结果一致。

BLOOD
IF23.1
2024-11-050
PRE
Effect of Intravenous Zoledronic Acid on Total Knee Replacement in Patients With Symptomatic Knee Osteoarthritis and Without Severe Joint Space Narrowing: A Prespecified Secondary Analysis of a Two-Year, Multicenter, Double-Blind, Placebo-Controlled Clinical Trial

静脉注射唑来膦酸对无严重关节间隙狭窄的有症状膝骨关节炎患者全膝关节置换术的影响: 一项为期两年的多中心、双盲、安慰剂对照临床试验的预设二次分析

2024-03-132
OAAI
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care
2023-07-015
OAAI
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
2023-02-0715
OA
Patients Recently Treated for B-lymphoid MalignanciesShow Increased Risk of Severe COVID-19

最近接受B淋巴恶性肿瘤治疗的患者出现严重新型冠状病毒肺炎的风险增加

2022-03-0913
OA
Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium

老年癌症患者严重新型冠状病毒肺炎结局的老年危险因素: 来自新型冠状病毒肺炎和癌症协会的队列研究

2022-03-0115
OA
BRE12-158: A post-neoadjuvant, randomized phase 2 trial of personalized therapy vs. treatment of physician's choice for patients with residual triple negative breast cancer
2022-02-150
PRE